Nanjing Vazyme Biotech Past Earnings Performance
Past criteria checks 1/6
Nanjing Vazyme Biotech's earnings have been declining at an average annual rate of -42%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 5.5% per year. Nanjing Vazyme Biotech's return on equity is 0.6%, and it has net margins of 1.7%.
Key information
-42.0%
Earnings growth rate
-77.6%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 5.5% |
| Return on equity | 0.6% |
| Net Margin | 1.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Nanjing Vazyme Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,403 | 24 | 731 | 307 |
| 30 Jun 24 | 1,364 | 26 | 714 | 309 |
| 31 Mar 24 | 1,285 | -15 | 703 | 324 |
| 31 Dec 23 | 1,286 | -71 | 702 | 339 |
| 30 Sep 23 | 2,133 | -232 | 843 | 373 |
| 30 Jun 23 | 2,520 | -101 | 903 | 411 |
| 31 Mar 23 | 2,896 | 112 | 917 | 410 |
| 31 Dec 22 | 3,569 | 594 | 911 | 396 |
| 30 Sep 22 | 2,885 | 878 | 730 | 352 |
| 30 Jun 22 | 2,663 | 900 | 663 | 303 |
| 31 Mar 22 | 2,302 | 773 | 587 | 263 |
| 31 Dec 21 | 1,869 | 678 | 511 | 230 |
| 30 Sep 21 | 1,715 | 767 | 432 | 188 |
| 31 Dec 20 | 1,564 | 822 | 290 | 126 |
| 31 Dec 19 | 268 | 26 | 144 | 62 |
| 31 Dec 18 | 171 | 1 | 93 | 53 |
Quality Earnings: 688105 has a large one-off gain of CN¥209.2M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 688105 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688105's earnings have declined by 42% per year over the past 5 years.
Accelerating Growth: 688105 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 688105 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).
Return on Equity
High ROE: 688105's Return on Equity (0.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 12:19 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nanjing Vazyme Biotech Co., Ltd is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Yuan Gao | China International Capital Corporation Limited |
| Jin Zhang | China International Capital Corporation Limited |